Korean J Hematol 1999; 34(2):
Published online June 30, 1999
© The Korean Society of Hematology
이승현, 최석영, 박태규, 이동화, 김희식, 이재성, 이찬우, 정성복, 이경희, 현명수
포항성모병원 내과,
영남대학교 의과대학 내과학교실
Prolymphocytic leukemia (PL) is usually derived from B cells and shares some features with chronic lymphocytic leukemia (CLL), but it is clearly a distinct entity and defined to have more than 55% prolymphocytes. Chronic lymphocytic leukemia/prolymphocytic leukemia (CLL/PL) is a mixed type of CLL and is defined to have 11∼55% prolymphocytes with intermediate features between CLL and PL. We Experienced two different cases of leukemia PL and CLL/PL. On physical examination, PL (stage II, B) patient showed multiple cervical lymph node enlargement and 5㎝ sized splenomegaly and hepatomegaly. But CLL/PL (stage III, C) patient showed 10㎝ sized splenomegaly and no lymph node enlargement. Onimmunological phenotyping, surface markers showed 72% CD5 (+), 85% CDl9 (+), and 40% Smlg (+) in PL patient and 3% CD5 (+), 90% CDl9 (+) and Smlg (-) in CLL/PL patient. PL patient was refractory to chlorambucil and prednisolone chemotherapy and showed poor prognosis. CLL/PL patient did not show remarkable response to chlorambucil and prednisolone therapy.
Keywords Prolymphocytic leukemia, Chronic lymphocytic leukemia, Chronic lymphocytic leukemia/prolymphocytic leukemia
Korean J Hematol 1999; 34(2): 344-348
Published online June 30, 1999
Copyright © The Korean Society of Hematology.
이승현, 최석영, 박태규, 이동화, 김희식, 이재성, 이찬우, 정성복, 이경희, 현명수
포항성모병원 내과,
영남대학교 의과대학 내과학교실
Seung Hyun Lee, Seuk Young Choi, Tae Gyu Park, Dong Hwa Lee, Hee Sik Kim, Jae Sung Lee, ChanWoo Lee, SeongPok Cheong, Kyung Hee Lee, Myung Soo Hyun
Department of Internal Medicine, Pohang St. Mary, 's Hospital, Pohang
College of Medicine, Yeung Nam University, Taegu, Korea
Prolymphocytic leukemia (PL) is usually derived from B cells and shares some features with chronic lymphocytic leukemia (CLL), but it is clearly a distinct entity and defined to have more than 55% prolymphocytes. Chronic lymphocytic leukemia/prolymphocytic leukemia (CLL/PL) is a mixed type of CLL and is defined to have 11∼55% prolymphocytes with intermediate features between CLL and PL. We Experienced two different cases of leukemia PL and CLL/PL. On physical examination, PL (stage II, B) patient showed multiple cervical lymph node enlargement and 5㎝ sized splenomegaly and hepatomegaly. But CLL/PL (stage III, C) patient showed 10㎝ sized splenomegaly and no lymph node enlargement. Onimmunological phenotyping, surface markers showed 72% CD5 (+), 85% CDl9 (+), and 40% Smlg (+) in PL patient and 3% CD5 (+), 90% CDl9 (+) and Smlg (-) in CLL/PL patient. PL patient was refractory to chlorambucil and prednisolone chemotherapy and showed poor prognosis. CLL/PL patient did not show remarkable response to chlorambucil and prednisolone therapy.
Keywords: Prolymphocytic leukemia, Chronic lymphocytic leukemia, Chronic lymphocytic leukemia/prolymphocytic leukemia
Jun Ho Yi, Gyeong-Won Lee, Ji Hyun Lee, Kwai Han Yoo, Chul Won Jung, Dae Sik Kim, Jeong-Ok Lee, Hyeon Seok Eom, Ja Min Byun, Youngil Koh, Sung Soo Yoon, Jin Seok Kim, Jee Hyun Kong, Ho-Young Yhim, Deok-Hwan Yang, Dok Hyun Yoon, Do Hyoung Lim, Won-Sik Lee, Ho-Jin Shin
Blood Res 2021; 56(4): 243-251Nisha Marwah, Manali Satiza, Niti Dalal, Sudhir Atri, Monika Gupta, Sunita Singh, Rajeev Sen
Blood Res 2021; 56(1): 26-30Mesut Göçer, Erdal Kurtoğlu
Blood Res 2020; 55(4): 206-212